Search

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.16 -0.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.03

Max

18.58

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-607K

-51M

Pardavimai

-28M

100M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-51.215

Darbuotojai

1,784

EBITDA

4.1M

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+68.6% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-279M

2.1B

Ankstesnė atidarymo kaina

18.38

Ankstesnė uždarymo kaina

18.16

Naujienos nuotaikos

By Acuity

100%

0%

322 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-29 23:56; UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

2026-07-29 23:56; UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

2026-07-29 23:56; UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

2026-07-29 23:52; UTC

Social Media
News

Robinhood Markets reported record Q2 revenue of $1.31 billion but shares are lower in after-market trading due to a drop in cryptocurrency revenue and revised expense outlook.

2026-07-29 23:51; UTC

Social Media
Correlated Moves
News

Hecla Mining reported positive Q2 exploration results, extending high-grade mineralization at Keno Hill and Midas. Shares are higher in after-market trading.

2026-07-29 23:51; UTC

Social Media
News

PennyMac Mortgage Investment Trust's Q2 EPS of $0.23 missed estimates, with revenue at $73 million. Shares are trading lower in after-market hours.

2026-07-29 23:51; UTC

News

Five9 Inc will join the S&P SmallCap 600 index, effective August 3, 2026. Shares are higher in after-market trading following the announcement.

2026-07-29 23:51; UTC

News

General Motors Co shares declined in after-market hours as Ford's strong earnings and guidance overshadowed its outlook amid broader market pressures.

2026-07-29 23:51; UTC

Social Media
News

American Water Works reported strong Q2 earnings and revenue but shares declined slightly in after-market hours, reflecting broader market trends.

2026-07-29 23:46; UTC

Social Media
News

DoorDash Inc launches DoorDash Air, a new drone delivery unit. Shares are higher in after-market trading, continuing recent upward momentum.

2026-07-29 23:46; UTC

News

Avis Budget Group reported second-quarter earnings below expectations, with revenue at $3 billion and EPS of $0.98. Shares are lower in after-market hours.

2026-07-29 23:46; UTC

News
Correlated Moves

Entegris Inc. announced board changes, with Bertrand Loy retiring in 2026. Shares are higher in after-market hours, reflecting a broader Nasdaq 100 increase.

2026-07-29 23:41; UTC

News

Claros Mortgage Trust reported a second-quarter net loss of $255.4 million, contributing to a decline in after-market trading. Shares are lower.

2026-07-29 23:41; UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

2026-07-29 23:41; UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

2026-07-29 23:41; UTC

News

Churchill Downs shares fell after reporting Q2 adjusted EPS of $3.45, slightly missing estimates, and announcing plans to explore property sales.

2026-07-29 23:41; UTC

Social Media
News

Meta Platforms reported second-quarter earnings below expectations, with net income declining to $15.85 billion. Shares fell sharply in after-market trading amid rising costs.

2026-07-29 23:41; UTC

Social Media
News

Qualcomm Inc shares fell in after-market trading following weaker-than-expected guidance and a profit decline in its third-quarter fiscal 2026 results.

2026-07-29 23:41; UTC

Social Media
News

Modine Manufacturing reported first-quarter net income of $73.9 million, but shares declined in after-market trading following mixed results and revenue that missed estimates.

2026-07-29 23:36; UTC

News

Antero Resources shares are lower in after-market trading following a second-quarter earnings report that included an adjusted EPS miss and mixed operational results.

2026-07-29 23:36; UTC

News

Peabody Energy announced a quarterly dividend of $0.075 per share after reporting $1 billion in revenue, despite a net loss of $90.6 million. Shares rose in after-market trading.

2026-07-29 23:32; UTC

News

Invitation Homes reported strong Q2 results, with net income rising to $218.2 million. Shares are trading higher in after-market hours following the earnings report.

2026-07-29 23:32; UTC

News

AXT Inc secures an $87 million supply agreement with Lumentum for indium phosphide wafers, boosting its strategic position in the semiconductor market during after-market hours.

2026-07-29 23:31; UTC

News

Saia Inc shares are higher in after-market trading as the company prepares to report earnings. It exceeded revenue expectations with $806.2 million last session.

2026-07-29 23:31; UTC

News

DMC Global Inc reported second-quarter sales of $157 million, exceeding estimates. Shares are trading higher in after-market hours following the results.

2026-07-29 23:31; UTC

Social Media
News

Lam Research Corp reported strong second-quarter earnings, with adjusted EPS of $1.82 and optimistic guidance for Q3, driving shares higher in after-market trading.

2026-07-29 23:31; UTC

News

iShares 7-10 Year Treasury Bond ETF trades lower in after-hours, reflecting market caution amid geopolitical tensions and concerns about rising interest rates and inflation.

2026-07-29 23:31; UTC

News

Vanguard Total Bond Market ETF declines in after-market trading amid rising geopolitical tensions and concerns over inflation and interest rates affecting market sentiment.

2026-07-29 23:31; UTC

News

RenaissanceRe Holdings increased its share buyback program to $750 million and declared a quarterly dividend of $0.41, driving shares higher in after-market trading.

2026-07-29 23:26; UTC

News

Ford Motor Co reported adjusted earnings of $0.42 per share, raising its 2026 guidance and prompting shares to rise in after-market trading.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

68.6% į viršų

12 mėnesių prognozė

Vidutinis 30.87 USD  68.6%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

322 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat